DRESS syndrome in response to Denosumab: First documented case report

Denosumab is an antiresorptive drug targeting RANK ligand, currently licensed for postmenopausal and male osteoporosis, bone loss associated with hormone ablation in men with prostate cancer and with systemic glucocorticoid treatment, and also used in oncology for the treatment of bone metastases an...

Descripción completa

Detalles Bibliográficos
Autores principales: Al-Attar, Mariam, De Santis, Maria, Massarotti, Marco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6933223/
https://www.ncbi.nlm.nih.gov/pubmed/31890758
http://dx.doi.org/10.1016/j.bonr.2019.100239

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6933223/
https://www.ncbi.nlm.nih.gov/pubmed/31890758
http://dx.doi.org/10.1016/j.bonr.2019.100239

Ejemplares similares